Worth reading
35Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Announced details
Applicable field (uses covered by this announcement)
IR for individual investors; the biotechnology industry and drug discovery business
Launch date7 October 2026 (held)
Relationship between the counterparty and the company
PRISM BioLab Co.,LTD206A
Relationship with the Company
The Company presented at the seminar, which was hosted by Logmi Finance.
CounterpartyLogmi Finance
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Source (materials cited by the company)
Logmi Finance
| Item | Details |
|---|---|
| Counterparty | Logmi Finance |
| Relationship with the Company | The Company presented at the seminar, which was hosted by Logmi Finance. |
| Launch date | 7 October 2026 (held) |
| Applicable area | IR for individual investors; the biotechnology industry and drug discovery business |
| Source | Logmi Finance |
Items this document does not state (13)
Names of Products / Services CoveredCounterparty overviewContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To promote dialogue with shareholders and investors and advance IR activities aimed at enhancing corporate value.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.